Brief: BioArctic Says Leqembi Approved For The Treatment Of Alzheimer's Disease In UAE
Aug 13 (Reuters) - BioArctic AB BIOAb.ST :
* LEQEMBI APPROVED FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IN THE
UNITED ARAB EMIRATES
* BIOARCTIC AB - IN CLARITY AD STUDY, LEQEMBI MET ITS
PRIMARY
ENDPOINT AND ALL KEY SECONDARY ENDPOINTS WITH STATISTICALLY
SIGNIFICANT RESULTS
Source text for Eikon: ID:nWkr4m0SZS
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million